Pds biotech announces two abstracts accepted for presentation at the 2022 american society of clinical oncology annual meeting

Florham park, n.j., april 27, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary versamune® and infectimune™ t-cell activating technologies, today announced the titles of two abstracts accepted for poster presentations during the 2022 american society of clinical oncology (asco) annual meeting being held from june 3-7, 2022.
PDSB Ratings Summary
PDSB Quant Ranking